Funding for this research was provided by:
Oesterreichische Nationalbank (15173)
Innovative Medicines Initiative (ITCC-P4)
Fellinger Krebsforschung (2017)
Austrian Science Fund (T906, P30105)
Österreichischen Akademie der Wissenschaften (DOC-Fund)
Received: 24 June 2019
Accepted: 18 July 2019
First Online: 7 August 2019
Ethics approval and consent to participate
: The study was approved by the ethics committee of the Medical University of Vienna and by the local ethics committee of Upper Austria in Linz. Informed consent was obtained from all participating patients and/or legal representatives.
: Not applicable.
: The authors declare that they have no competing interests.